Pharma 101 - Pharmaceutical Fraud
« Eli Lilly and Company in More Hot Water
Clinical investigator indicted for fraud in pharmaceutical trials of blockbuster drug »

Purdue Pharma Agrees to $19.5 Million Settlement Over Off Label Marketing of OxyContin

Purdue Pharma has agreed to settle claims by 26 states and the District of Columbia for marketing and promoting OxyContin for unapproved uses i.e. for use every 8 hours as opposed to the FDA approved dosage of every 12 hours.  The states alleged that FDA rules were violated by Purdue promoting OxyContin as the painkiller “to start with and the one to stay with” for numerous kinds of pain even though the drug was specifically approved a more limited use in patients who need long-term pain management.  Further, the states contend that Purdue paid its sales force based on how much physicians prescribed OxyContin which led to the “misuse, diversion and abuse” of OxyContin according to Connecticut Attorney General Richard Blumenthal. Pursuant to the $19.5 million settlement, Purdue must immediately stop its off-label marketing and heed the warning label contained on its packaging.
 

To read more click here or more about pharmaceutical fraud at Nolan & Auerbach.

, , , ,
Posted By Marcella Auerbach
Category Legal, Off-Label Posted May 25th, 2007
Bookmark

Leave a Reply

 

Regulatory Documents (PDF)

Nolan Law Firm Articles
Site Sponsored By:

Nolan & Auerbach, P.A. is a qui tam law firm whose practice is uniquely limited to healthcare fraud cases under the qui tam provisions of the False Claims Act. We know healthcare fraud because that's what we do! Toll free: 800-FRAUD 04

"The hiring of a lawyer is an important decision that should not be based
solely on advertisements. Before you decide, ask us to send you free written
information about our qualifications and experience."

Licensed in Florida
Located in Fort Lauderdale, Florida
Available for National Cases